Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Capital Expenditures (2019 - 2025)

Pliant Therapeutics has reported Capital Expenditures over the past 7 years, most recently at -$262000.0 for Q4 2025.

  • Quarterly Capital Expenditures fell 225.36% to -$262000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$150000.0 through Mar 2026, down 105.73% year-over-year, with the annual reading at $112000.0 for FY2025, 97.09% down from the prior year.
  • Capital Expenditures was -$262000.0 for Q4 2025 at Pliant Therapeutics, down from $262000.0 in the prior quarter.
  • Over five years, Capital Expenditures peaked at $3.4 million in Q3 2024 and troughed at -$1.6 million in Q4 2022.
  • The 5-year median for Capital Expenditures is $186000.0 (2023), against an average of $246900.0.
  • The largest YoY upside for Capital Expenditures was 3537.23% in 2024 against a maximum downside of 310.95% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at -$1.3 million in 2021, then fell by 22.24% to -$1.6 million in 2022, then surged by 103.83% to $61000.0 in 2023, then surged by 242.62% to $209000.0 in 2024, then tumbled by 225.36% to -$262000.0 in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Capital Expenditures are -$262000.0 (Q4 2025), $262000.0 (Q3 2025), and -$150000.0 (Q2 2025).